It is important to note that even responders to anti-EGFR therapy routinely develop secondary resistance during anti-EGFR therapy, often by selection of KRAS/NRAS or BRAF-mutant clones arising from a RAS-wildtype cancer [97–99]. The gene discussed is KRAS; the disease is cancer.